<![CDATA[Lung Cancer Update]]>ddb91215-1abc-5c0f-b674-04adad480f0aFri, 27 Feb 2026 21:32:32 +0000Captivate.fmDr. Neil Lovehttps://artwork.captivate.fm/230421a8-7e2e-4fb0-b40c-3b50a1cbf78f/nstTehQJgx-Rm0qFgD_28hl9.pngLung Cancer UpdateDr. Neil LoveDr. Neil LoveFeaturing one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.https://www.researchtopractice.com/browse-tumor-types/lung-cancerfalseepisodichttps://feeds.captivate.fm/lung-cancer-update/nopodcastExtensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance TherapyExtensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance TherapyDr Hossein Borghaei from Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Anne Chiang from Yale Cancer Center in New Haven, Connecticut, discuss key clinical trial data in the first-line management of ES-SCLC, real-world case studies and current patterns of care among oncologists.

CME information and select publications here.

]]>Dr Hossein Borghaei from Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Anne Chiang from Yale Cancer Center in New Haven, Connecticut, discuss key clinical trial data in the first-line management of ES-SCLC, real-world case studies and current patterns of care among oncologists.

CME information and select publications here.

]]>f638406f-58ff-47a7-ad47-ca2afe84dde8Fri, 27 Feb 2026 15:30:00 -050059:42falsefull24373724Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance TherapyExtensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance TherapyDr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid and Dr Shields from Indiana University School of Medicine in Indianapolis discuss key datasets surrounding first-line and maintenance therapy for patients with extensive-stage small cell lung cancer and their clinical implications. 

CME information and select publications here.

]]>Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid and Dr Shields from Indiana University School of Medicine in Indianapolis discuss key datasets surrounding first-line and maintenance therapy for patients with extensive-stage small cell lung cancer and their clinical implications. 

CME information and select publications here.

]]>1a129e61-6eea-4e4d-89bc-4f4fa2bf19ebWed, 17 Dec 2025 12:00:00 -050057:46falsefull24363624Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology NetworkLung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology NetworkDr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer.

CME information and select publications here.

]]>Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer.

CME information and select publications here.

]]>455fa50e-82b3-4802-9e8d-ad8b797f18c8Fri, 12 Dec 2025 14:00:00 -050001:43:11falsefull24353524HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V HeymachHER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V HeymachDr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for HER2-altered non-small cell lung cancer.   

CME information and select publications here.

]]>Dr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for HER2-altered non-small cell lung cancer.   

CME information and select publications here.

]]>4b99109a-423f-4ca4-8d02-fbfc9e590dc0Wed, 10 Dec 2025 08:30:00 -050001:05:13falsefull24343424Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesLung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesDr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. 

CME information and select publications here.

]]>Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. 

CME information and select publications here.

]]>57d5c575-32d1-4e2e-ab7d-f4468f73cffaMon, 10 Nov 2025 14:00:00 -050021:21falsefull24333324Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesLung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesDr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. 

CME information and select publications here.

]]>Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. 

CME information and select publications here.

]]>838baf77-70da-4f36-bd48-5bbe16f020f6Mon, 20 Oct 2025 14:00:00 -050024:47falsefull24323224Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesNon-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesDr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer. 

CME information and select publications here.

]]>Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer. 

CME information and select publications here.

]]>611a4d2d-0405-4e40-99b7-bb2e6d80f2ffSun, 14 Sep 2025 08:00:00 -050023:19falsefull24313124Small Cell Lung Cancer — Expert Perspectives on Actual Patient CasesSmall Cell Lung Cancer — Expert Perspectives on Actual Patient CasesDr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for patients with limited-stage and extensive-stage small cell lung cancer. 

CME information and select publications here.

]]>Dr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for patients with limited-stage and extensive-stage small cell lung cancer. 

CME information and select publications here.

]]>262a4630-4bbf-4bf4-ac7c-bcd840394813Fri, 22 Aug 2025 16:00:00 -050058:18falsefull24303024Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesNon-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesDr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. 

CME information and select publications here.

]]>Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. 

CME information and select publications here.

]]>b51d74a0-4dbb-4395-abe9-178c3adac00eMon, 18 Aug 2025 15:00:00 -050017:44falsefull24292924Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and AdvancesNon-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and AdvancesDr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies for localized and advanced non-small cell lung cancer without a targetable mutation. 

CME information and select publications here.

]]>Dr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies for localized and advanced non-small cell lung cancer without a targetable mutation. 

CME information and select publications here.

]]>d755cd82-e980-4e79-aca5-1b58ef497e43Fri, 08 Aug 2025 11:00:00 -050059:02falsefull24282824Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug ConjugatesLung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug ConjugatesProf Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations. 

CME information and select publications here.

]]>Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations. 

CME information and select publications here.

]]>9eb2f6f3-3409-40aa-bee9-767bda6dac76Thu, 17 Jul 2025 14:00:00 -050001:28:41falsefull24272724For Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS CongressDr Anne Chiang, Dr Erin Schenk, and nurse practitioners Ms Elizabeth Krueger and Ms Beth Sandy discuss the role of bispecific antibodies in the management of small cell lung cancer and strategies to mitigate and manage treatment-emergent adverse events. 

NCPD information and select publications here.

]]>Dr Anne Chiang, Dr Erin Schenk, and nurse practitioners Ms Elizabeth Krueger and Ms Beth Sandy discuss the role of bispecific antibodies in the management of small cell lung cancer and strategies to mitigate and manage treatment-emergent adverse events. 

NCPD information and select publications here.

]]>0ca4e3fe-3b5c-4f9e-9c9d-3c257432b917Tue, 08 Jul 2025 09:00:00 -050001:27:39falsefull24262624EGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual MeetingEGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual MeetingProf Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing treatment decision-making for EGFR-mutated NSCLC at the 2025 ASCO annual meeting. 

CME information and select publications here.

]]>Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing treatment decision-making for EGFR-mutated NSCLC at the 2025 ASCO annual meeting. 

CME information and select publications here.

]]>4f3fa74e-e1e0-4c7d-a323-0139560eff5eFri, 20 Jun 2025 10:00:00 -050001:57:51falsefull24252524Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and AdvancesNon-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and AdvancesDr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer. 

CME information and select publications here.

]]>Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer. 

CME information and select publications here.

]]>fe808dde-98b9-40b0-b0fe-d6a0524f9728Tue, 10 Jun 2025 15:00:00 -050058:22falsefull24242424Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology SummitImmunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches.  

CME information and select publications here.

]]>9f83b985-830b-453f-bb08-196f139c7e81Sun, 18 May 2025 09:00:00 -050050:15falsefull24232324EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology SummitEGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer.  

CME information and select publications here.

]]>ae53e414-baa4-41aa-b296-55becf1cd1aaWed, 30 Apr 2025 09:00:00 -050052:17falsefull24222224For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS CongressDr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. 

NCPD information and select publications here.

]]>Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. 

NCPD information and select publications here.

]]>f7051937-5d34-40dd-be02-8d4b0b076ce5Sat, 26 Apr 2025 09:00:00 -050001:33:02falsefull24212124First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F GainorFirst-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F GainorDr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. 

CME information and select publications here.

]]>Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. 

CME information and select publications here.

]]>0b6938e6-5275-43c1-8a34-56961b032baeThu, 10 Apr 2025 15:13:00 -050057:28falsefull24202024EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and AdvancesEGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and AdvancesDr Enriqueta Felip from the Vall d’Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer. 

CME information and select publications here

]]>Dr Enriqueta Felip from the Vall d’Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer. 

CME information and select publications here

]]>ceba5fee-f027-46cb-aa3c-91528940fee5Thu, 06 Feb 2025 09:00:00 -050001:00:02falsefull24191924Cases from the Community: Integrating New Research Findings into Current Practice — Lung CancerCases from the Community: Integrating New Research Findings into Current Practice — Lung CancerDr Edward B Garon shares his perspectives on the evolving therapeutic landscape for patients with lung cancer.

]]>Dr Edward B Garon shares his perspectives on the evolving therapeutic landscape for patients with lung cancer.

]]>FAB0AF98-CC6E-468A-B9D2-C7EC552428E4Fri, 13 Dec 2024 12:06:00 -050048:03falsefull24181824Dr Edward B Garon shares his perspectives on the evolving therapeutic landscape for patients with lung cancer.Meet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung CancerMeet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung CancerDr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer.

]]>Dr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer.

]]>FB74D28B-5BEA-4F0C-8797-303F0340FBCDWed, 11 Dec 2024 12:25:00 -050058:47falsefull24171724Dr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer.The Implications of Recent Datasets for the Current and Future Management of Lung Cancer — A Review of Information from ESMO Congress 2024 and Other ConferencesThe Implications of Recent Datasets for the Current and Future Management of Lung Cancer — A Review of Information from ESMO Congress 2024 and Other ConferencesDr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York discuss the implications of recent data sets for the current and future management of lung cancer.

]]>Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York discuss the implications of recent data sets for the current and future management of lung cancer.

]]>CEFFB83E-0200-48FB-BCC6-420CB978479BMon, 25 Nov 2024 13:04:00 -050001:00:12falsefull24161624Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia   and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York discuss the implications of recent data sets for the current and future management of lung cancer.Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Lung CancerData + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Lung CancerSpecialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer.

]]>Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer.

]]>1208A2A5-0269-44C3-8B00-BC135D60DC51Fri, 15 Nov 2024 21:43:00 -050001:05:42falsefull24151524Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer.Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from Recent Major ConferencesOncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from Recent Major ConferencesDr Stephen V Liu from Georgetown University Hospital in Washington, DC, reviews recently presented data with and newly approved therapies for localized and advanced lung cancers.

]]>Dr Stephen V Liu from Georgetown University Hospital in Washington, DC, reviews recently presented data with and newly approved therapies for localized and advanced lung cancers.

]]>42F6B9F1-8B7A-4B75-8354-BFBD2F626134Thu, 07 Nov 2024 12:03:00 -050054:40falsefull24141424Dr Stephen V Liu from Georgetown University Hospital in Washington, DC, reviews recently presented data with and newly approved therapies for localized and advanced lung cancers.The Implications of Recent Datasets for the Current and Future Management of Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer ReviewThe Implications of Recent Datasets for the Current and Future Management of Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer ReviewDr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer.

]]>Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer.

]]>4922AF06-2FD3-48B6-8D89-3F1AE955CE22Wed, 23 Oct 2024 12:48:00 -050042:46falsefull24131324Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer.The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung CancerThe Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung CancerDr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations.

]]>Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations.

]]>B45C3CA6-31CD-4A17-B252-5C709245CE42Wed, 16 Oct 2024 12:49:00 -050001:00:08falsefull24121224Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations.The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFRThe Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFRDr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR.

]]>Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR.

]]>D18A4575-AC29-4108-A4E3-62BF16BE7F61Tue, 08 Oct 2024 12:37:00 -050058:14falsefull24111124Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR.The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR MutationsThe Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR MutationsDr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations.

]]>Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations.

]]>4688ADB4-C5CA-428B-B0B8-9B3BB4CC2B42Wed, 02 Oct 2024 11:53:00 -050058:19falsefull24101024Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations.Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine TumorsInside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine TumorsDr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors.

]]>Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors.

]]>55B1339F-8A4D-49D2-816B-250E2420A1A7Thu, 19 Sep 2024 08:23:00 -050059:20falsefull249924Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors.Striving for Consensus: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR MutationStriving for Consensus: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR MutationDr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation.

]]>Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation.

]]>2B347D1E-976B-429E-97B7-7BB7D1D9F267Thu, 12 Sep 2024 10:33:00 -050002:03:23falsefull248824Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation.Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung CancerInside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung CancerProf Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting.

]]>Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting.

]]>55C63509-0421-4DB6-8D92-66060BB1D732Wed, 21 Aug 2024 11:23:00 -050001:01:24falsefull247724Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting.Oncology Today with Dr Neil Love: Novel Agents and Strategies in Lung CancerOncology Today with Dr Neil Love: Novel Agents and Strategies in Lung CancerDr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Manish Patel from Florida Cancer Specialists & Research Institute in Sarasota, Florida, summarize recently presented advancements, including novel strategies, in the treatment of lung cancer.

]]>Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Manish Patel from Florida Cancer Specialists & Research Institute in Sarasota, Florida, summarize recently presented advancements, including novel strategies, in the treatment of lung cancer.

]]>0BAA82A5-6A42-456F-A803-8B35D7E67F0FWed, 14 Aug 2024 11:36:00 -050001:01:43falsefull246624Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Manish Patel from Florida Cancer Specialists & Research Institute in Sarasota, Florida, summarize recently presented advancements, including novel strategies, in the treatment of lung cancer.Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung CancerYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung CancerDr Matthew Gubens from the University of California, San Francisco summarizes important 2023 datasets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations.

]]>Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 datasets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations.

]]>860EE03D-A8CB-4B8D-95F4-8FDCD2359C00Mon, 05 Aug 2024 10:21:00 -050001:00:53falsefull245524Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 datasets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations.Oncology Today with Dr Neil Love: An interview with Jonathan W Goldman, MD — Management of Non-Small Cell Lung Cancer with an EGFR MutationOncology Today with Dr Neil Love: An interview with Jonathan W Goldman, MD — Management of Non-Small Cell Lung Cancer with an EGFR MutationDr Jonathan W Goldman from UCLA Health in Santa Monica, California summarizes recent developments presented at ASCO 2024 for patients with non-small cell lung cancer with an EGFR mutation.

]]>Dr Jonathan W Goldman from UCLA Health in Santa Monica, California summarizes recent developments presented at ASCO 2024 for patients with non-small cell lung cancer with an EGFR mutation.

]]>E5D7DC95-98B4-4C0F-87B2-F279B4E5DEC0Thu, 25 Jul 2024 12:12:00 -050047:35falsefull244424Dr Jonathan W Goldman from UCLA Health in Santa Monica, California summarizes recent developments presented at ASCO 2024 for patients with non-small cell lung cancer with an EGFR mutation.Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung CancerYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung CancerDr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets.

]]>Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets.

]]>EBC737B9-C09D-438C-88A6-53A8818F9E4DWed, 12 Jun 2024 11:44:00 -050001:00:48falsefull243324Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets.Oncology Today with Dr Neil Love: The Emerging Role of B7-H3-Targeted Antibody-Drug ConjugatesOncology Today with Dr Neil Love: The Emerging Role of B7-H3-Targeted Antibody-Drug ConjugatesDr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors.

]]>Dr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors.

]]>4C99F02B-EC66-4D7A-A0AC-ABC9C915BB44Thu, 04 Apr 2024 09:38:00 -050001:14:03falsefull242224Dr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors.Oncology Today with Dr Neil Love: Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung CancerOncology Today with Dr Neil Love: Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung CancerDr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with established and investigational targets in patients with non-small cell lung cancer.

]]>Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with established and investigational targets in patients with non-small cell lung cancer.

]]>7C9226E6-54B5-453D-B9CF-5BF49D00F37CWed, 20 Mar 2024 09:17:00 -050001:02:58falsefull241124Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with established and investigational targets in patients with non-small cell lung cancer.Implications of Recent Data Sets for the Current and Future Management of Lung CancerImplications of Recent Data Sets for the Current and Future Management of Lung CancerDr Luis Paz-Ares from the National Oncology Research Center in Madrid, Spain, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, and Dr David R Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss key presentations from the 2023 ESMO Congress for the management of lung cancer.

]]>Dr Luis Paz-Ares from the National Oncology Research Center in Madrid, Spain, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, and Dr David R Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss key presentations from the 2023 ESMO Congress for the management of lung cancer.

]]>4F414A46-408E-40AE-BBDD-537A6BA82DF3Mon, 11 Dec 2023 11:06:00 -050001:30:17falsefull23101023Dr Luis Paz-Ares from the National Oncology Research Center in Madrid, Spain, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, and Dr David R Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss key presentations from the 2023 ESMO Congress for the management of lung cancer.Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung CancerInside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung CancerDr Jamie Chaft and Dr John Heymach discuss the optimal integration of targeted therapy and immunotherapy into the care of patients with localized non-small cell lung cancer.

]]>Dr Jamie Chaft and Dr John Heymach discuss the optimal integration of targeted therapy and immunotherapy into the care of patients with localized non-small cell lung cancer.

]]>E038CEAA-94AA-477C-B307-C53F4D8E9BC4Mon, 16 Oct 2023 09:49:00 -050001:01:40falsefull239923Dr Jamie Chaft and Dr John Heymach discuss the optimal integration of targeted therapy and immunotherapy into the care of patients with localized non-small cell lung cancer.Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor TherapyStriving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor TherapyDr Corey Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands discuss the optimal current management of relapsed NSCLC and provide perspectives on the future of care for patients with this disease.

]]>Dr Corey Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands discuss the optimal current management of relapsed NSCLC and provide perspectives on the future of care for patients with this disease.

]]>D35B9FBD-1999-4380-99FA-B451914F0146Fri, 08 Sep 2023 16:28:00 -050002:43:37falsefull238823Dr Corey Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands discuss the optimal current management of relapsed NSCLC and provide perspectives on the future of care for patients with this disease.Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingOncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingFeaturing a discussion on key presentations on lung cancer from the 2023 ASCO Annual Meeting, with Dr Matthew Gubens, moderated by Dr Neil Love.

]]>Featuring a discussion on key presentations on lung cancer from the 2023 ASCO Annual Meeting, with Dr Matthew Gubens, moderated by Dr Neil Love.

]]>4980AFD3-E116-4158-95D6-7FC63ADE8A45Tue, 22 Aug 2023 11:34:00 -050032:16falsefull237723Featuring a discussion on key presentations on lung cancer from the 2023 ASCO Annual Meeting, with Dr Matthew Gubens, moderated by Dr Neil Love.Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung CancerYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung CancerProceedings from our Year in Review webinar on immunotherapy and other nontargeted approaches for lung cancer. Featuring perspectives from Drs Luis Paz-Ares and Heather Wakelee, moderated by Dr Neil Love.

]]>Proceedings from our Year in Review webinar on immunotherapy and other nontargeted approaches for lung cancer. Featuring perspectives from Drs Luis Paz-Ares and Heather Wakelee, moderated by Dr Neil Love.

]]>F775B152-656A-4CB5-875F-2EA0003B8047Mon, 01 May 2023 10:09:00 -050001:03:20falsefull236623Proceedings from our Year in Review webinar on immunotherapy and other nontargeted approaches for lung cancer. Featuring perspectives from Drs Luis Paz-Ares and Heather Wakelee, moderated by Dr Neil Love.Recent Advances and Future Directions in Lung Cancer — With Dr Ibiayi Dagogo-Jack and Stephen Liu (Proceedings from a Symposium in Partnership with NCOA and SCOS)Recent Advances and Future Directions in Lung Cancer — With Dr Ibiayi Dagogo-Jack and Stephen Liu (Proceedings from a Symposium in Partnership with NCOA and SCOS)Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

]]>Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

]]>919AF46E-4312-41F3-80E2-9D18B80ECFF0Fri, 17 Mar 2023 12:20:00 -050059:05falsefull235523Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.Striving for Consensus on the Management of ALK-Positive Lung CancerStriving for Consensus on the Management of ALK-Positive Lung CancerFeaturing a discussion on the management of ALK-positive lung cancer with Dr Ross Camidge, Dr Justin Gainor, Prof Solange Peters and Prof Ben Solomon, moderated by Dr Neil Love.

]]>Featuring a discussion on the management of ALK-positive lung cancer with Dr Ross Camidge, Dr Justin Gainor, Prof Solange Peters and Prof Ben Solomon, moderated by Dr Neil Love.

]]>6BF0F166-6A5E-4C55-BFAE-0F9423930B55Mon, 06 Mar 2023 08:46:00 -050002:29:53falsefull234423Featuring a discussion on the management of ALK-positive lung cancer with Dr Ross Camidge, Dr Justin Gainor, Prof Solange Peters and Prof Ben Solomon, moderated by Dr Neil Love.Oncology Today with Dr Neil Love: Management of HER2-Altered Non-Small Cell Lung Cancer?Oncology Today with Dr Neil Love: Management of HER2-Altered Non-Small Cell Lung Cancer?Featuring a discussion on targeted therapy for HER2-altered non-small cell lung cancer with Dr Bob Li, moderated by Dr Neil Love.

]]>Featuring a discussion on targeted therapy for HER2-altered non-small cell lung cancer with Dr Bob Li, moderated by Dr Neil Love.

]]>803DF12F-AE87-4B5C-8F00-645B2701EC31Tue, 21 Feb 2023 09:10:00 -050001:20:06falsefull233323Featuring a discussion on targeted therapy for HER2-altered non-small cell lung cancer with Dr Bob Li, moderated by Dr Neil Love.Oncology Today with Dr Neil Love: Management of Metastatic Non-Small Cell Lung Cancer without an Actionable MutationOncology Today with Dr Neil Love: Management of Metastatic Non-Small Cell Lung Cancer without an Actionable MutationFeaturing a discussion on new and emerging data in the management of NSCLC without an actionable mutation, with Dr Edward Garon, moderated by Dr Neil Love.

]]>Featuring a discussion on new and emerging data in the management of NSCLC without an actionable mutation, with Dr Edward Garon, moderated by Dr Neil Love.

]]>9C19BD08-589B-48DC-AB30-52531D400A55Mon, 13 Feb 2023 11:22:00 -050049:37falsefull232223Featuring a discussion on new and emerging data in the management of NSCLC without an actionable mutation, with Dr Edward Garon, moderated by Dr Neil Love.Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung CancerYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung CancerProceedings from our Year in Review webinar on targeted therapy for non-small cell lung cancer. Featuring perspectives from Drs Zofia Piotrowska and Gregory Riely, moderated by Dr Neil Love.

]]>Proceedings from our Year in Review webinar on targeted therapy for non-small cell lung cancer. Featuring perspectives from Drs Zofia Piotrowska and Gregory Riely, moderated by Dr Neil Love.

]]>13ED6869-F0A2-4836-9781-7FF1C19B91DATue, 24 Jan 2023 10:45:00 -050001:00:16falsefull231123Proceedings from our Year in Review webinar on targeted therapy for non-small cell lung cancer. Featuring perspectives from Drs Zofia Piotrowska and Gregory Riely, moderated by Dr Neil Love.